Work

Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz095.029

Authors: L.M. Smyth, C. Saura, S.A. Piha-Paul, J. Lu, I.A. Mayer, A.M. Brufksy, I. Spanggaard, M. Arnedos, R.E. Cutler, D.M. Hyman

Institutions: St. Vincent's University Hospital, Vall d'Hebron Hospital Universitari, The University of Texas MD Anderson Cancer Center, USC Norris Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Copenhagen University Hospital, Rigshospitalet, Institut Gustave Roussy, Puma Biotechnology (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2946047270

FWCI: 2.388

Cites:

Cited by: 17

Related to: 10